Who Paid My Doc
Sara Vargas
Anatomic Pathology & Clinical Pathology Boston, MA Medical Doctor
NPI 1679584718 CMS profile 439256
300 Longwood Ave, Boston, MA 02115
General payments
$5,800
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Sara Vargas of Boston, MA is reported in the CMS Open Payments database as having received $5,800 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $5,800 | 1 |
Beside peers
- Sara Vargas
- Anatomic Pathology & Clinical Pathology median
- Middle half of Anatomic Pathology & Clinical Pathology
- National median
In program year 2025, general payments to Sara Vargas were reported at $0. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.
Show as a table
| Year | Sara Vargas | Anatomic Pathology & Clinical Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $65 | $22–$150 | $163 |
| 2020 | $0 | $44 | $19–$144 | $114 |
| 2021 | $0 | $42 | $19–$142 | $132 |
| 2022 | $5,800 | $54 | $20–$140 | $149 |
| 2023 | $0 | $60 | $23–$157 | $160 |
| 2024 | $0 | $51 | $23–$145 | $164 |
| 2025 | $0 | $51 | $24–$149 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$3,456
Medicare patients
32
Services billed
99
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 53% | |
| COPD | 53% | |
| Depression | 50% | |
| Arthritis | 50% | |
| Chronic kidney disease | 47% | |
| Cancer | 44% | |
| Ischemic heart disease | 41% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anatomic Pathology & Clinical Pathology in Massachusetts
Jason Baron
Anatomic Pathology & Clinical Pathology · Boston, MA
Thomas Gould
Anatomic Pathology & Clinical Pathology · Holyoke, MA
Rosina Lis
Anatomic Pathology & Clinical Pathology · Westborough, MA
Manlio Loconte
Anatomic Pathology & Clinical Pathology · Boston, MA
Gretchen Frieling
Anatomic Pathology & Clinical Pathology · Wellesley Hills, MA
Franklin Moore
Anatomic Pathology & Clinical Pathology · Springfield, MA
Related records
Anatomic Pathology & Clinical Pathology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Anatomic Pathology & Clinical Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.